Searched for
ZAYNICH LAUNCH IN US
Zydus Therapeutics' saroglitazar drug granted priority review by US FDAZydus Therapeutics' drug saroglitazar has received priority review from the US FDA. This drug treats primary biliary cholangitis, a liver d...28 May, 2026, 09.51 PM IST- US FDA review boosts odds for Wockhardt’s NCE success story: Vishal ManchandaWockhardt’s breakthrough respiratory drug Zaynich moves a step closer to market as the US FDA accepts it for review, boosting approval odds...02 Dec, 2025, 09.11 AM IST
- USFDA accepts Wockhardt’s NDA for breakthrough antibiotic ZaynichThis is the first time ever that an NDA from a new chemical entity (NCE) from an Indian pharma company has been filed and accepted by the U...01 Dec, 2025, 07.47 PM IST
- Wockhardt activates Zaynich push, eyes global licensing dealsWockhardt is advancing Zaynich, a novel antibiotic combination, targeting drug-resistant infections, with plans for regulatory submissions ...01 Jul, 2025, 05.11 AM IST
- Wockhardt eyes USD 7 billion market opportunity for antibiotic Zaynich in US, EuropeWockhardt's new antibiotic, Zaynich, targeting gram-negative infections, anticipates a significant USD 7 billion market in the US and Europ...05 Jun, 2025, 05.28 PM IST
- Can Zaynich do for Wockhardt what Ozempic did for Novo Nordisk?Wockhardt's Zaynich antibiotic surged stock by 75%. CEO Habil Khorakiwala cited its uniqueness; phase three trials end this fiscal year. Co...06 Jul, 2024, 11.12 AM IST
- Wockhardt soars to 6-year highWockhardt's stock soared 20% as Zaynich antibiotic treated a US cancer patient with Pseudomonas infection at Children's Hospital of Orange ...02 Jul, 2024, 07.28 AM IST
- Wockhardt raises Rs 480 crore to pare debt, fund drug trialWockhardt plans to clear debt, fund antibiotic trials with QIP funds. Khorakiwala expects revenue growth, EBITDA rise, and completion of gl...28 Mar, 2024, 11.56 PM IST
Load More
